Trius Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious infections. The Company is developing tedizolid phosphate, a new, novel antibiotic, for the treatment of serious Gram-positive bacterial infections, including those caused by methicillin-resistant staphylococcus aureus, or MRSA. Tedizolid phosphate is being developed for acute bacterial skin and skin structure infections, or ABSSSI, and pneumonia, and for other indications. ABSSSI is the current classification for complicated skin and skin structure infections. In addition, the Company is discovering antibiotics for infections caused by Gram-negative bacteria using the structure based discovery platform. As on December 2012, the Company completed enrollment in the second Phase III clinical trial, the ESTABLISH 2 (TR701-113) study, of the intravenous to oral transition therapy for the treatment of ABSSSI.